Core Viewpoint - The recent IPOs of Baiaosaitu and Baoji Pharmaceutical have seen significant first-day gains, reflecting strong market sentiment towards the biotech sector and the potential for high returns from innovative products [1][4]. Group 1: Company Performance - Baiaosaitu achieved a first-day closing price increase of 146.6%, with a total market capitalization reaching 29.41 billion yuan. The company reported revenues of approximately 534 million yuan, 717 million yuan, and 980 million yuan for the years 2022 to 2024, respectively, and turned a profit of 33.54 million yuan in 2024 after previous losses [3][5]. - Baoji Pharmaceutical, on the other hand, closed up 138.8% on its first day, with a market capitalization of 20.54 billion HKD. The company has not yet achieved profitability, reporting revenues of 6.93 million yuan, 6.16 million yuan, and 41.99 million yuan for 2023, 2024, and the first half of 2025, respectively, alongside significant losses [3][6]. Group 2: Market Trends - In 2023, a total of 8 biotech stocks were listed on the A-share market, with 6 of them experiencing first-day gains exceeding 100%. The most notable was Danase Biotechnology, which surged by 497.08% on its debut [7]. - The Hong Kong market saw 24 biotech IPOs this year, with 19 stocks rising on their first day, and only 3 stocks experiencing a decline. The highest gain was recorded by Yinnuo Pharmaceutical at 206.48% [8][9]. Group 3: Investor Sentiment - The significant increases in stock prices for these new biotech listings are attributed to optimistic expectations regarding the high growth potential of the biotech industry and the scarcity of new IPOs, which has driven investor sentiment [4].